The co-founder discovered ‘lacritin’, a natural tear protein selectively deficient in dry eye and yet when added topically to eyes of dry eye animals restores basal tearing without irritation and homeostasis of the eye surface.
TearSolutions has developed a proprietary synthetic fragment of lacritin, Lacripep™. Lacripep™ is water soluble, stable in human tears, and equipotent to lacritin. Enrollment of a 201 patient phase 2 trial of Lacripep™ in Primary Sjogren’s Syndrome is now complete with results expected in 2020.